New State PBM Rules Put Pharmacy Access Ahead of Quick Drug-Price Promises

A fresh wave of state laws is putting pharmacy benefit managers under tighter scrutiny as prescription costs remain a household worry. The most practical benefit for patients may not be an immediate price cut, but a clearer fight over pharmacy access, rebates and the hidden mechanics that shape what people pay at the counter.

The Associated Press reported June 27 that lawmakers in at least a dozen states have passed PBM laws this year, while legislators in at least 26 states introduced more than 120 PBM-related bills. Those efforts are aimed at companies that manage pharmacy claims for insurers, negotiate drug-price terms and help decide which medications and pharmacies are covered.

What changed for patients and local pharmacies

The new rules vary by state, but the common thread is transparency and leverage. Some measures limit spread pricing, where a PBM charges a health plan more than it reimburses a pharmacy. Others require rebates or discounts to be passed through, set minimum payments to pharmacies, or put new disclosure duties on companies that administer prescription benefits.

Kansas is one clear example. The Kansas Department of Insurance said its Consumer Prescription Protection and Accountability Act requires PBMs to pass drug rebates to health plans, bans spread pricing, aims to protect patient choice and gives the department more tools for transparency and accountability. The department said it was preparing for implementation on July 1, 2026.

Louisiana has also moved on pharmacy reimbursement. In Directive 257, the Louisiana Department of Insurance said PBMs subject to state law must bring compensation programs into compliance where reimbursement formulas fall below the National Average Drug Acquisition Cost plus a required $9 amount for a 30-day supply. The directive frames the issue around whether local pharmacies are being paid under formulas that are fair and reasonable under state law.

Why this matters on Main Street

Prescription costs are not a niche budget problem. KFF said earlier this year that about six in 10 U.S. adults were at least somewhat worried about affording prescription drugs, and about four in 10 reported that costs had led them to skip, delay, reduce or substitute medication in the past year. That makes the PBM debate practical rather than procedural: if local pharmacies close or formularies become harder to navigate, the cost is measured in time, travel and missed medicine, not only in dollars.

For independent pharmacies, the issue is also a Main Street business story. AP reported that PBMs, especially the largest companies, handle most U.S. prescriptions. Pharmacy owners and their advocates argue that low or opaque reimbursements can make it harder for small pharmacies to stay open, especially in rural communities where a closed pharmacy can mean a long drive for routine medications.

The second-layer takeaway is that cheaper medicine and pharmacy access are not always the same policy problem. A rule that helps keep a local pharmacy solvent may protect access for seniors and rural patients, while a rule that increases transparency may help employers and regulators push for better plan terms. Neither automatically cuts a family's copay this month. But together, they can make the prescription system less of a black box.

The limits are real

This is not a simple good-news story. PBMs say they use scale to negotiate lower drug costs and encourage generic-drug use. Critics of mandatory dispensing fees call them potential pill taxes. CVS has sued over Tennessee's PBM ownership law, according to AP, and the article noted that even some PBM critics question whether state-by-state regulation can fully solve a national drug-pricing system.

Federal changes are coming, but many are delayed. KFF's review of the 2026 federal appropriations law says Congress enacted PBM provisions including rebate pass-through requirements for many employer health plans and future transparency rules for Medicare Part D and employer plans, with several important requirements beginning in 2028 or later. That timing matters for households: rules passed now may change contracts before they change a receipt.

What patients should watch next

• Whether state insurance departments publish enforcement guidance before new PBM rules take effect.
• Whether health plans explain if rebates or PBM savings will lower premiums, deductibles, copays or only plan-level costs.
• Whether local pharmacies remain in-network after new reimbursement or ownership rules are challenged.
• Whether patients can compare an insurance copay against the cash price before filling a prescription.

For now, the practical move is modest but useful: patients should ask pharmacists whether the cash price is lower than the insured price, check whether a preferred local pharmacy remains in-network at renewal, and watch notices from employers or insurers about prescription-benefit changes. The policy fight is complicated, but the household question is plain: will the system become easier to understand before costs force people to skip care?